Holen Sie sich die Stockscreener-App
40.55
1.69%
0.6993
Schlusskurs vom Vortag:
$39.85
Offen:
$40.485
24-Stunden-Volumen:
743.68K
Relative Volume:
0.17
Marktkapitalisierung:
$82.52B
Einnahmen:
$40.95B
Nettoeinkommen (Verlust:
$5.16B
KGV:
18.68
EPS:
2.1708
Netto-Cashflow:
$5.47B
1W Leistung:
-0.94%
1M Leistung:
+2.16%
6M Leistung:
+4.61%
1J Leistung:
-0.45%
1-Tages-Spanne:
$40.36
$40.57
1-Wochen-Bereich:
$39.29
$40.93
52-Wochen-Spanne:
$31.71
$42.63
Gsk Plc Adr Stock (GSK) Company Profile
Vergleichen Sie GSK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
40.56 | 80.20B | 40.95B | 5.16B | 5.47B | 2.1708 |
|
LLY
Lilly Eli Co
|
717.35 | 649.52B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
180.30 | 432.80B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
220.50 | 389.72B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
123.46 | 239.37B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
78.29 | 196.23B | 63.43B | 16.42B | 14.72B | 6.49 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
Sound Income Strategies LLC Has $16.56 Million Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Clean Yield Group - MarketBeat
Top Technology Executives Recognized at the 2025 BayAreaCIO ORBIE Awards - GlobeNewswire Inc.
TD Private Client Wealth LLC Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Pneumococcal Vaccine Market Opportunities and Strategies to 2034 - GlobeNewswire Inc.
Miller Howard Investments Inc. NY Purchases 13,023 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Rhumbline Advisers Increases Holdings in GSK PLC Sponsored ADR $GSK - Defense World
Parallel Advisors LLC Acquires 1,718 Shares of GSK PLC Sponsored ADR $GSK - Defense World
First Bank & Trust Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Rep. Lisa C. McClain Purchases Shares of GSK PLC Sponsored ADR (NYSE:GSK) - MarketBeat
Bard Financial Services Inc. Raises Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Douglas Lane & Associates LLC Decreases Stake in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Acquired by First Hawaiian Bank - MarketBeat
GSK (NYSE:GSK) Stock Unloaded Rep. Robert B. Aderholt - MarketBeat
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):